Neuren Pharmaceuticals Limited: Expansion of DAYBUE STIX Availability in the US
Neuren Pharmaceuticals Limited (ASX: NEU) has announced the broad availability of DAYBUE® STIX (trofinetide) in the United States, marking a significant advancement in the treatment of Rett syndrome for patients aged two years and older. The formulation, approved by the FDA in December 2025, offers a dye- and preservative-free powder that can be mixed with various liquids, enhancing ease of administration and patient compliance.
Initial feedback from early users has been encouraging, with over 80% of caregivers reporting satisfaction, particularly highlighting its flexibility and portability. Expert consensus further reinforces trofinetide as a standard-of-care treatment, emphasizing early initiation and sustained usage to optimize patient outcomes. Neuren continues to leverage its partnership with Acadia Pharmaceuticals for commercialization while advancing its broader pipeline, including NNZ-2591, targeting multiple neurodevelopmental disorders through ongoing clinical trials.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Neuren Pharmaceuticals Limited: Expansion of DAYBUE STIX Availability in the US
Neuren Pharmaceuticals Limited (ASX: NEU) has announced the broad availability of DAYBUE® STIX (trofinetide) in the United States, marking a significant advancement in the treatment of Rett syndrome for patients aged two years and older. The formulation, approved by the FDA in December 2025, offers a dye- and preservative-free powder that can be mixed with various liquids, enhancing ease of administration and patient compliance.
Initial feedback from early users has been encouraging, with over 80% of caregivers reporting satisfaction, particularly highlighting its flexibility and portability. Expert consensus further reinforces trofinetide as a standard-of-care treatment, emphasizing early initiation and sustained usage to optimize patient outcomes. Neuren continues to leverage its partnership with Acadia Pharmaceuticals for commercialization while advancing its broader pipeline, including NNZ-2591, targeting multiple neurodevelopmental disorders through ongoing clinical trials.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au